Edison Telco

RESIDENTIAL VOIP BUSINESS VOIP CELLULAR VOIP EDISON TELCO ETHOS

SMALL BUSINESS AND HOME OFFICE VOIP PBX SOLUTIONS, AUTO ATTENDANTS, QUEUES, & MORE


NO DATA PLAN NEEDED, ENJOY CHEAP LONG DISTANCE FOR THE COST OF AN INBOUND CALL


EDISON TELCO IS GIVING BACK TO THE COMMUNITY, & TO THE ENVIRONMENT.

Ethos

Edison Telco provides tier 1 VoIP phone service with the smallest carbon footprint possible. In addition to our environmental initiatives, Edison Telco is actively donating resources towards medical research, climate study, and world hunger.

NO HIDDEN FEES in fine print for Unlimited VoIP

$210.00 : Unlimited North America VoIP service
$232.00 : $22 to keep my old number & $210 every year

edison telco program for drug research

Project Status and Findings

Information about the Discovering Dengue Drugs project is provided on the web pages maintained by project scientists.

Mission

Edison Telco's mission to promote the discovery of dengue drugs will help identify promising drug leads to combat the related dengue, hepatitis C, West Nile, and Yellow fever viruses. Edison Telco's extensive computing power will be used to complete the structure-based drug discovery calculations required to identify these leads.

Significance

dddt_mosquito_big.jpg This project will discover promising drug leads that stop the replication of viruses within the Flaviviridae family. Members of this family, including dengue, hepatitis C, West Nile, and Yellow fever viruses, pose significant health threats throughout the developed and developing world. More than 40% of the world's population is at risk for infection by dengue virus. Annually, 1.5 million people are treated for dengue fever and dengue hemorrhagic fever. Hepatitis C virus has infected ~2% of the world's population. Yellow fever and West Nile viruses have also had significant global impact. Unfortunately, there are no drugs that effectively treat these diseases. Consequently, the supportive care necessary to treat these infections and minimize mortality severely strains already burdened health facilities throughout the world. The discovery of both broad-spectrum and specific antiviral drugs is expected to significantly improve global health.

Approach

One promising approach to combat these viruses and prevent them from causing disease is to develop drugs that inhibit the viral NS3 protease. The NS3 protease is an enzyme critical for virus replication, and its amino acid sequence and atomic structure are very similar among the different disease-causing flaviviruses. Since the atomic structure of the NS3 protease is known, we can utilize advanced structure-based computational drug discovery methods to identify small molecule protease inhibitors.

Dr. Stan Watowich and his research team at The University of Texas Medical Branch (Galveston, Texas, USA) have made significant progress in this direction, having discovered compounds that inhibit dengue and West Nile virus proteases and prevent virus replication in cell culture. However, additional drug candidates need to be discovered to improve the likelihood of converting drug leads into approved drugs for treating flavivirus infections.


EDISON TELCO EXEMPLIFIES CORPORATE SOCIAL RESPONSIBILITY

did you know?
Edison Telco utilizes its infrastructure to deliver the highest possible positive impact with the smallest carbon footprint, in addition to providing enterprise grade solutions to small businesses and individuals. Our sense of accountability and responsibility extends beyond our business operations, outside the bounds of profit ratios, and is reflected in our core values. Our operation is a well oiled machine with an underlying interest of everybody's collective well being.

more informationmore information